

**Treatment-Experienced Patients With Prior Partial Response  
All Patients**

**TABLE 112: SVR GENOTYPE 1 TREATMENT-EXPERIENCED WITH PARTIAL RESPONSE:  
RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM  
EFFECTS MODEL**

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
T12 PR48 q8	PR48	3.88 (1.21 to 6.43)	37.80 (2.44 to 54.42)
SIM12 PR48		4.25 (1.85 to 7.08)	42.14 (10.22 to 59.45)
B32 PR36-48 RGT		3.67 (1.16 to 7.87)	34.70 (2.09 to 68.53)
PAR/RIT12 + OMB12 + DAS12		6.52 (2.35 to 10.53)	73.36 (16.24 to 86.02)
PAR/RIT12 + OMB12 + DAS12 + RBV12		7.19 (4.05 to 11.41)	80.99 (38.60 to 88.41)
DCV24 + ASU24		5.43 (2.59 to 8.80)	57.90 (19.75 to 73.41)
DCV24 + ASU24 + PR24		6.17 (1.72 to 9.90)	68.74 (8.30 to 81.31)
SIM12 PR48	T12 PR48 q8	1.09 (0.71 to 2.46)	4.31 (−14.09 to 29.46)
B32 PR36-48 RGT		0.95 (0.34 to 3.03)	−2.23 (−38.11 to 44.63)
PAR/RIT12 + OMB12 + DAS12		1.66 (1.03 to 3.59)	33.87 (1.06 to 57.93)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.82 (1.32 to 4.86)	41.75 (16.36 to 68.76)
DCV24 + ASU24		1.38 (0.98 to 3.28)	19.35 (−0.91 to 45.62)
DCV24 + ASU24 + PR24		1.57 (0.87 to 2.97)	29.35 (−3.26 to 48.37)
B32 PR36-48 RGT	SIM12 PR48	0.87 (0.29 to 2.25)	−6.84 (−43.16 to 38.70)
PAR/RIT12 + OMB12 + DAS12		1.53 (0.72 to 2.81)	29.92 (−11.51 to 54.65)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.67 (1.23 to 3.10)	37.29 (11.68 to 58.72)
DCV24 + ASU24		1.27 (0.74 to 2.47)	15.17 (−13.77 to 42.10)
DCV24 + ASU24 + PR24		1.45 (0.56 to 2.45)	25.31 (−17.20 to 46.68)
PAR/RIT12 + OMB12 + DAS12	B32 PR36-48 RGT	1.75 (0.64 to 4.85)	36.11 (−19.74 to 71.01)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.93 (0.98 to 5.62)	44.48 (−1.16 to 75.75)
DCV24 + ASU24		1.47 (0.64 to 4.39)	22.14 (−24.55 to 58.75)
DCV24 + ASU24 + PR24		1.65 (0.51 to 4.50)	31.61 (−24.96 to 65.70)
PAR/RIT12 + OMB12 + DAS12 + RBV12	PAR/RIT12 + OMB12 + DAS12	1.08 (0.76 to 2.56)	6.76 (−18.90 to 49.44)
DCV24 + ASU24		0.83 (0.50 to 1.83)	−14.82 (−40.86 to 26.51)
DCV24 + ASU24 + PR24		0.95 (0.38 to 1.72)	−4.66 (−43.23 to 28.59)
DCV24 + ASU24	PAR/RIT12 + OMB12 + DAS12 + RBV12	0.76 (0.42 to 1.16)	−22.14 (−50.36 to 8.75)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
DCV24 + ASU24 + PR24		0.88 (0.30 to 1.17)	-11.51 (-56.09 to 10.78)
DCV24 + ASU24 + PR24	DCV24 + ASU24	1.14 (0.42 to 1.77)	10.16 (-33.44 to 33.25)
Random effect model	Residual deviance	20.56 vs. 20 data points	
	Deviance information criteria	113.704	
Fixed effect model	Residual deviance	20.84 vs. 20 data points	
	Deviance information criteria	113.016	

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.